Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of October 3, 2026, VRTX trades at $508.15 with a market cap of $128.44B and a P/E ratio of 29.30. VRTX moved -0.40% today. Year to date, VRTX is +11.63%; over the trailing twelve months it is +23.45%. Its 52-week range spans $362.50 to $560.25. Analyst consensus is strong buy with an average price target of $576.57. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vertex Pharmaceuticals (VRTX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. VRTX moved -0.40% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $508.15 |
| Market Cap | $128.44B |
| P/E Ratio | 29.30 |
| EPS | $17.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $560.25 |
| 52-Week Low | $362.50 |
| Volume | 604.09K |
| Avg Volume | 0 |
| Revenue (TTM) | $12.59B |
| Net Income | $4.41B |
| Gross Margin | 86.00% |
25 analysts cover VRTX: 0 strong buy, 21 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $576.57.